Yahoo · Sep 2, 2026
Top Midday Gainers
Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of
NASDAQ · PPBT
Purple Biotech Ltd.
Healthcare · Biotechnology
$1.74
Down-$0.10 (-5.43%)
Updated Sep 11, 2026, 10:48 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.26K
- P/E ratio
- -0.92
- Dividend yield
- 0.00%
- 52-week range
- $1.16 – $14.10
- Volume
- 81.83K
- Avg. volume
- 7.21M
Price performance
PPBT price history
1M range · 20 trading sessions · Daily adjusted prices
PPBT closed at $1.74 after 20 trading sessions, up 16.39% for the selected period.
- Last close
- $1.74
- Period change
- +16.39%
- Period low
- $1.50
- Period high
- $1.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.85 | $1.88 | $1.7007 | $1.74 | 81.83K |
| Sep 9, 2026 | $1.71 | $1.84 | $1.70 | $1.84 | 135.85K |
| Sep 8, 2026 | $1.70 | $1.87 | $1.5667 | $1.80 | 277.18K |
| Sep 4, 2026 | $2.02 | $2.10 | $1.73 | $1.75 | 357.83K |
| Sep 3, 2026 | $2.00 | $2.07 | $1.75 | $1.98 | 1.03M |
| Sep 2, 2026 | $2.39 | $2.59 | $1.90 | $1.98 | 76.77M |
| Sep 1, 2026 | $1.70 | $1.7433 | $1.47 | $1.66 | 60K |
| Aug 31, 2026 | $1.67 | $1.74 | $1.67 | $1.70 | 12.69K |
| Aug 28, 2026 | $1.7899 | $1.80 | $1.66 | $1.68 | 38.36K |
| Aug 27, 2026 | $1.65 | $1.73 | $1.6312 | $1.66 | 16.82K |
| Aug 26, 2026 | $1.605 | $1.7985 | $1.605 | $1.73 | 67.83K |
| Aug 25, 2026 | $1.58 | $1.7499 | $1.5144 | $1.65 | 61.55K |
| Aug 24, 2026 | $1.54 | $1.56 | $1.52 | $1.56 | 17.67K |
| Aug 21, 2026 | $1.55 | $1.59 | $1.53 | $1.57 | 6.46K |
| Aug 20, 2026 | $1.59 | $1.6299 | $1.58 | $1.58 | 10.87K |
| Aug 19, 2026 | $1.63 | $1.64 | $1.57 | $1.59 | 18.14K |
| Aug 18, 2026 | $1.51 | $1.70 | $1.49 | $1.56 | 63.72K |
| Aug 17, 2026 | $1.50 | $1.57 | $1.4605 | $1.53 | 25.35K |
| Aug 14, 2026 | $1.4468 | $1.525 | $1.4414 | $1.50 | 11.14K |
| Aug 13, 2026 | $1.47 | $1.56 | $1.47 | $1.495 | 16.7K |
Latest PPBT news
The latest Smart Investors Daily articles mentioning PPBT.
Stock researchCompany · Overview
PPBT research
Overview
Company profile and research snapshot.
Company profile
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection
Purple Biotech (NASDAQ:PPBT) has received a U. S.
Yahoo · Sep 2, 2026
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands th
Benzinga · Sep 2, 2026
Why Is Purple Biotech Stock Gaining Wednesday?
Purple Biotech (PPBT) stock surged premarket after receiving a USPTO patent allowance for its CAPTN-3 tri-specific antibody platform.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
